Archives
-
Deferasirox in Ferroptosis and Iron-Metabolism Assays
2026-09-11
Deferasirox is an oral iron chelator that gives researchers a practical way to perturb labile iron, redox balance, and ferroptosis sensitivity in cellular models. This workflow-focused guide connects iron-overload biology with hepatocellular carcinoma research while separating validated findings from testable experimental hypotheses.
-
Sex Differences in Angiotensin II Hypertension
2026-09-11
Xue, Pamidimukkala, and Hay used radiotelemetry in conscious, freely moving mice to show that chronic angiotensin II produces a substantially greater hypertensive response in males than in females. Gonadectomy, baroreflex testing, and ganglionic blockade further linked this divergence to sex-dependent hormonal and autonomic regulation rather than to baseline blood pressure differences alone.
-
WNT5a/GSK3/β-Catenin Controls FAP Adipogenesis
2026-09-10
The reference study identifies the WNT5a/GSK3/β-catenin axis as a central regulator of adipogenic differentiation in skeletal muscle fibro/adipogenic progenitors (FAPs). By combining pharmacological perturbation, single-cell mass cytometry, transcriptomic integration, and mouse models, it links β-catenin stabilization to reduced PPARγ-driven adipogenesis and improved satellite-cell support.
-
PS Nanoplastics, NMNAT3, and Placental Ferroptosis
2026-09-10
This study identifies an NMNAT3-dependent metabolic cascade linking gestational polystyrene nanoplastic exposure to placental NAD+ depletion, mitochondrial dysfunction, ferritinophagy, ferroptosis, and fetal growth restriction. Its integrated metabolomics, cellular rescue, and nicotinamide-intervention strategy provides a mechanistic framework for investigating nanoplastic-induced reproductive toxicity and potential metabolic countermeasures.
-
Light-Inducible RNA Release for Regulated Gene Therapy
2026-09-09
A 2026 Trends in Biotechnology study presents a rationally designed light-inducible RNA-releasing protein (LIRP) that controls therapeutic protein production at the translation stage. By combining LIRP with AAV delivery and light-accessible tissues, the authors demonstrate reversible regulation in models of obesity and retinal neovascular disease, offering a safety-oriented framework for on-demand gene therapy.
-
Renal OCT2/MATE1 Inhibition by 5-HT3 Antagonists
2026-09-09
George and colleagues compared five 5-HT3 antagonist drugs in complementary cellular models of renal organic cation transport. Their results identify transporter-specific inhibition patterns and show that several agents, including tropisetron, can reduce OCT2/MATE1-dependent secretion in vitro, supporting further investigation of cationic drug interactions.
-
Cycloastragenol in Glucocorticoid-Induced Osteonecrosis
2026-09-08
A 2024 in vivo study shows that cycloastragenol reduced femoral-head necrosis and trabecular bone loss in a methylprednisolone-induced rat model of glucocorticoid-induced osteonecrosis of the femoral head. By combining micro-CT, angiography, histology, qPCR, and Western blotting, the study links structural preservation to reduced osteoclast activity and altered RANKL–OPG signaling, while leaving important translational questions unresolved.
-
Serine/Glycine-Free Diet and PD-L1 Lactylation
2026-09-08
The Cell Metabolism study by Tong et al. shows that a serine/glycine-free diet can inhibit colorectal cancer growth and increase cytotoxic T-cell activity, while simultaneously promoting immune evasion through PD-L1 lactylation. Its preclinical and early clinical findings support combining metabolic dietary intervention with immune checkpoint blockade, but randomized efficacy studies and more detailed clinical validation remain necessary.
-
GW4064 Workflow for FXR Metabolic Research
2026-09-07
GW4064 is a selective non-steroidal FXR agonist for connecting receptor activation with lipid homeostasis, bile acid transport, and cholestatic injury mechanisms. This guide translates its potency and formulation constraints into practical cell, transporter, and in vivo workflows.
-
H2S Deficiency and ER Stress in Diabetic Cardiomyopathy
2026-09-07
The reference study links reduced endogenous hydrogen sulfide production with lipid-driven myocardial injury, endoplasmic reticulum stress, and apoptosis in diabetic cardiomyopathy. By combining patient samples, streptozotocin-induced diabetic rats, and palmitate-treated cardiomyocytes, it shows that hydrogen sulfide replacement and ER-stress inhibition produce concordant protective effects.
-
Gramine–CUL3–MTDH Axis in TNBC Ferroptosis
2026-09-05
The reference study identifies Gramine as a selective suppressor of triple-negative breast cancer through a CUL3–MTDH regulatory pathway that activates ferroptosis. Its combination of target-engagement assays, genetic perturbation, ferroptosis rescue, and xenograft experiments provides a useful framework for mechanism-led cancer biology research.
-
Optimizing hiPSC Platelet Production: 2026 Study
2026-09-04
A 2026 study established an optimized differentiation scheme that improves megakaryocyte generation, platelet output, maturation, and production cost from human induced pluripotent stem cells. By combining a higher embryoid-body input, human platelet lysate, cytokine-replacing small molecules, and maturation-promoting compounds, the protocol produced functional platelets in 19 days.
-
PKH26 Red Fluorescent Cell Linker Kit Guide
2026-09-04
The PKH26 Red Fluorescent Cell Linker Kit provides red fluorescent labeling of cell membrane lipid regions for cell tracing and proliferation studies. It is intended for membrane-focused applications in vitro and in vivo, not for intracellular targets or non-membrane labeling.
-
Anlotinib and VEGFR2-Driven Tumor Angiogenesis
2026-09-03
The reference study established anlotinib as a highly potent, orally active VEGFR2 inhibitor that suppresses tumor angiogenesis across biochemical, endothelial, ex vivo, and xenograft models. Its strongest preclinical effect arose from vascular disruption rather than direct tumor-cell cytotoxicity, providing a useful framework for mechanistic cancer research and anti-angiogenic assay design.
-
Marein Inhibits ABCG2 to Restore Chemosensitivity
2026-09-03
The 2024 Biochemical Pharmacology study identifies marein, a flavonoid from Coreopsis tinctoria Nutt, as a competitive inhibitor of the ABCG2 drug efflux transporter. Functional, cellular, analytical, and target-engagement experiments link marein activity to increased intracellular chemotherapy exposure and restored sensitivity in ABCG2-expressing resistant cancer cells.